Fetal globin induction in β-thalassemia

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  El Beshlawy, Amal ^a   Hamdy, Mona ^a   El Ghamrawy, Mona ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Thalassemia; HbF inducers; Natural inducers; Pharmacological agents

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGELICIN; AZACITIDINE; BERGAMOT OIL; CYTOTOXIC AGENT; ERYTHROPOIETIN; HYDROXYUREA; RAPAMYCIN; RESVERATROL; SHORT CHAIN FATTY ACID;

BETA THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CONFERENCE PAPER; CONTROLLED STUDY;

BETA-THALASSEMIA; FETAL HEMOGLOBIN; GAMMA-GLOBINS; GENE EXPRESSION REGULATION; HUMANS;

EID: 73949104108     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903351882     Document Type: Conference Paper

References (23)

1. Weatherall DJ, Clegg JB. The thalassemia syndromes. In: Weatherall DJ, Clegg B, eds. The Thalassemia Syndromes. 4th ed. Oxford, UK: Blackwell Science; 2001:287-356.
2. Higgs DR, Thein SL, Woods WG. The physiology of the thalassemia. In: Weatherall DJ, Clegg B, eds. The Thalassemia Syndromes. 4th ed. Oxford, UK: Blackwell Science; 2001:265-284.
3. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2:245-255.
4. Gallo E, Massero P, Miniero R, David D, Tarella C. The importance of the genetic picture in globin synthesis in determining the clinical and hematological features of thalassemia intermedia. British Journal of Hematology. 1979;41:211-221.
5. Perrine SP. Fetal globin induction - can it cure beta thalassemia: Hematology. American Society of Hematology Education Program Book. 2005;38-44.
6. Ikuta T, Kan YW, Swerdlow PS, Faller DV, Perrine SP. Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. Blood. 1998;92(8):2924-2933.
7. De Simone J. The evolving role of DNA demethylating agents in the treatment of sickle cell disease and thalassemia. Semin Hematol. 2004;41(4 Suppl. 6):1-3.
8. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol. 2005;1727(2):125-133.
9. Loukopoulos D, Voskaridou E, Stamoulakatou A, et al. Clinical trials with hydroxyurea and recombinant human erythropoietin. In Stamatoyannapoulos, G. and Nienhuis, AW (eds), Hemoglobin Switching. New York: Alan R. Liss. 1995;365-372.
10. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenyl butyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 1995;85(1):43-49.
11. Perrine SP, Yang YM, Piga A, et al. Butyrate+EPO in beta thalassemia intermedia: interim findings of a phase II trial [abstract]. Blood. 2002;100:47a.
12. Cappellini MD, Graziadei G, Ciceri L. Oral isobutyramide therapy in patients with thalassemia intermedia: results of phase II open study. Blood Cells Mol Dis. 2000;26(1):105-111.
13. Mankidy R, Faller DV, Mabaera R. Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NcoR repressor complex. Blood. 2006;108(9):3179-3186.
14. Ley TJ, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med. 1982;307(24):1469-1475.
15. Fathallah H, Atweh GF. DNA hypomethylation therapy for hemoglobin disorders molecular mechanisms and clinical applications. Blood Rev. 2006;20(4):227-234.
16. Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol. 2008;83(5):366-370.
17. Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol. 2005;84(7):441-446.
18. El Beshlawy A, Abou EL-Ela M, El-Ghamrawy M, Abdel-Salam A, Gaafar T, Mostafa A. The clinical and hematological responses to hydroxyurea in children with thalassemia intermedia. [U11]TIF 11th International Conference on Thalassemia and Haemoglobinopathies, Singapore, October 8-11, 2008, ALT06: 99.
19. Taher A, Ismaeel H, Cappellini M. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006(13):117-122.
20. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380-385.
21. Lampronti I, Bianchi N, Boratti M, Fibach E, Prus E, Gambari R. Accumulation of gamma globulin mRNA in human erythroid cells treated with angelicin. Eur J Haematol. 2003;71:189-195.
22. Gamabari R. Novel trends for the discovery and characterization of modifiers of globin gene expression. 10th International Thalassemia Conference, Cairo, May 6-7, 2009.
23. Bianchi N, Zuccato C, Borgatti M, Bergamini P, Gambari R. Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of b-thalassemia and sickle-cell anemia. Evid Based Complement Alternat. 2009;6(2):141-151.